3 ·Filed Aug 17, 2026

MAZE

Maze Therapeutics, Inc.
NEUTRAL
Impact 1/10
Horizonimmediate Processed1mo ago SEC0001341161-26-000003
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

This is a routine administrative filing with no trading or financial implications. Monitor future Form 4 filings for any insider transactions by Johnson, which would provide actionable signals.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
MAZE ▼ -16.58% at T+20d
NEUTRAL call ✗ call lost -16.58% · α vs SPY -15.59% · entry $29.13 → $24.30
Next anchor: T+60d in 6w
Latest observation: T+29 +1.01% FF3 residual α
Entry anchored
Aug 17, 04:00 PM ET
via 1-min bar
T+1d
+2.13%
call +2.13% · α +1.92%
$29.75
settled 6w ago
T+5d
+4.43%
call +4.43% · α +4.63%
$30.42
settled 6w ago
T+20d
-16.58%
call -16.58% · α -15.59%
$24.30
settled 17d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Paula A. Johnson filed a Form 3 initial statement of beneficial ownership with Maze Therapeutics, Inc., indicating her appointment as an officer and/or director. The filing is a routine administrative requirement for new insiders and contains no material financial information or trading activity.

Key Facts

  • Paula A. Johnson filed a Form 3 initial statement of beneficial ownership with Maze Therapeutics, Inc.
  • The filing is dated August 13, 2026, and was accepted on August 17, 2026.
  • A Limited Power of Attorney was also filed, authorizing Jason Coloma, Courtney Phillips, and Misbah Tahir to execute Section 16 filings on her behalf.
  • No beneficial ownership amounts or securities transactions are disclosed in the filing.

Financial Impact

No financial impact — the filing is a routine initial ownership statement with no disclosed holdings or transactions.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001341161-26-000003
Document: 0001341161-26-000003-index-headers.html0001341161-26-000003
Document: 0001341161-26-000003-index.html0001341161-26-000003
Document: 0001341161-26-000003.txt0001341161-26-000003
19 reports for MAZE
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+5▲ +5.16%Jun 3, 2026
Filters
Rows
Reports for MAZE — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 2/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 3/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 2, 2026
29d ago
144
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 1, 2026
4w ago
144
NEUTRAL ★ 3/10
$26.72 $24.82▼ −7.11%▼ −6.15%$26.69 (−0.12%)
Aug 17, 2026
6w ago
3
NEUTRAL ★ 1/10
$29.13 $30.42▲ +4.43%▲ +4.63%$26.69 (−8.38%)
Aug 11, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$27.53 $29.75▲ +8.06%▲ +8.51%$26.69 (−3.06%)
Aug 7, 2026
8w ago
Institutional Cluster
BULLISH ★ 5/10
$28.65 $27.18▼ −5.13%▼ −5.53%$26.69 (−6.85%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.81 $27.53▼ −1.01%▼ −1.36%$26.69 (−4.04%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$31.26 $32.42▲ +3.71%▲ +2.78%$26.69 (−14.63%)
Showing 10 of 19

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access